Olverembatinib for heavily pretreated BCR::ABL1-positive leukemia, including resistance or intolerance to ponatinib and/or asciminib
@article{ATM137645,
author = {Yasushi Kubota},
title = {Olverembatinib for heavily pretreated BCR::ABL1-positive leukemia, including resistance or intolerance to ponatinib and/or asciminib},
journal = {Annals of Translational Medicine},
volume = {13},
number = {2},
year = {2025},
keywords = {},
abstract = {},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/137645}
}